Curanex Pharmaceuticals (NASDAQ:CURX) Trading Down 8.7% – What’s Next?

Curanex Pharmaceuticals Inc (NASDAQ:CURX) shares were down 8.7% on Friday . The company traded as low as $0.3007 and last traded at $0.3030. Approximately 111,359 shares were traded during mid-day trading, an increase of 70% from the average daily volume of 65,523 shares. The stock had previously closed at $0.3320.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded shares of Curanex Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a report on Friday, May 1st. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has an average rating of “Sell”.

Curanex Pharmaceuticals Trading Down 8.7%

The stock has a market cap of $8.59 million and a PE ratio of -1.12. The company’s 50 day moving average is $0.40 and its 200-day moving average is $0.39.

Curanex Pharmaceuticals (NASDAQ:CURX) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.11) EPS for the quarter.

Hedge Funds Weigh In On Curanex Pharmaceuticals

A hedge fund recently bought a new stake in Curanex Pharmaceuticals stock. Citadel Advisors LLC acquired a new position in Curanex Pharmaceuticals Inc (NASDAQ:CURX) during the third quarter, according to the company in its most recent filing with the SEC. The fund acquired 64,067 shares of the company’s stock, valued at approximately $46,000.

About Curanex Pharmaceuticals

Curanex is a developmental stage pharmaceutical company dedicated to discovering, developing and commercializing innovative botanical drugs to treat patients suffering from inflammatory diseases. Our mission is to address significant unmet medical needs and improve patients’ lives by harnessing the power of natural substances. We are dedicated to discovering, developing and commercializing botanical medicines for treating patients with immune and inflammatory diseases and to develop therapies that may offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections.